NICE says drug to treat Batten disease cannot be recommended for NHS use because company is unable to address concerns about long-term effectiveness
NICE has published draft guidance which confirms its earlier decision not to recommend cerliponase alfa (also called Brineura and made by Biomarin) for children with Batten disease – a very rare inherited condition affecting between 1 and 6 babies each year in the UK.
Shared Learning Awards: Judges reveal 20 shortlisted entries to be displayed at NICE annual conference
More than 60 entries received from organisations across the country which highlight how they put NICE guidance into practice
NICE draft guidance recommends pertuzumab for new breast cancer indication after improved price offer from company
NICE has published final draft guidance recommending pertuzumab (Perjeta, Roche) for treating early HER2-positive breast cancer in people whose disease has spread to their lymph nodes.
NICE provides first scientific advice on patient preference study design
The NICE Scientific Advice team, working with the Science Policy and Research team at NICE, has provided its first piece of advice on the design of a patient preference study.
Latest news headlines
-
Diagnose Lyme disease if bull’s eye rash is present, says NICE
People showing erythema migrans, the characteristic skin rash associated with Lyme disease, can be diagnosed without the need for blood tests, NICE says in new guidance.
12 February 2019
-
.jpg?v=636855689287267058)
NICE and Public Health England publish new antibiotic prescribing guidance for patients with suspected pneumonia
These two guidelines set out an antimicrobial prescribing strategy that aims to optimise antibiotic use and reduce antibiotic resistance.
12 February 2019
-
NICE updates guideline on alcohol education in schools
NICE is updating its guideline on Alcohol interventions in secondary and further education.
08 February 2019
-
NICE collaborates with the Canadian Agency for Drugs and Technology in Health to offer parallel scientific advice
NICE and the Canadian Agency for Drugs and Technology in Health (CADTH) have launched a new collaboration to offer parallel scientific advice to the life sciences industry.
06 February 2019
-
%20small%20square.jpg?v=636846053489698326)
NICE recommends another revolutionary CAR T-cell therapy for adults with lymphoma
Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will be able to access another revolutionary chimeric antigen receptor T-Cell (CAR T-cell) therapy through the Cancer Drugs Fund.
01 February 2019
-
NICE Scientific Advice launches collaborative programme with life sciences industry body
NICE has announced a collaboration with the body which represents life sciences organisations in the UK.
29 January 2019